Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 701–800 of 1,000
Al-Dulaymi, M., Michel, D. L., Chitanda, J. M., El‐Aneed, A., Verrall, R. E., Grochulski, P., & Badea, I. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00480 · Cited by 11
Wu, Y., Lin, X., Hong, H., Fung, Y. L., Cao, X., Tse, J. K. Y., Li, T. H., Chan, T., & Tian, X. Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113172 · Cited by 11
Jeong, H., Purja, S., & Kim, E. Y. (2024) · Gene Therapy · doi:10.1038/s41434-023-00437-7 · Cited by 11
“Therefore, despite controversies about safety and potential risks, research and development in this fi eld are steadily expanding [2, 6 – 9].”
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 13
Cancer nanomedicine: Smart arsenal in the war against cancer
Ullah, M., Awan, U. A., Muhaymin, A., Naeem, M., Yoo, J., Mehreen, A., Safdar, A., Hasan, N., Haider, A., & Din, F. U. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114030 · Cited by 13
Janich, C., Pinnapireddy, S. R., Erdmann, F., Groth, T., Langner, A., Bakowsky, U., & Wölk, C. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.12.007 · Cited by 10
Magalhães, M., Figueiras, A., & Veiga, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813627-0.00007-7 · Cited by 11
Delivery Methods, Resources and Design Tools in CRISPR/Cas
Aslam, M. A., Hammad, M., Ahmad, A., Altenbuchner, J., & Ali, H. (2021) · Springer eBooks · doi:10.1007/978-981-15-7142-8_3 · Cited by 17
Li, Y., & Zhou, L. (2021) · BioEssays · doi:10.1002/bies.202100086 · Cited by 11
Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1837 · Cited by 11
Vaz, T. A. G., Rodrigues, A. F., & Coroadinha, A. S. (2023) · Biotechnology Journal · doi:10.1002/biot.202300212 · Cited by 10
In Utero Gene Therapy and its Application in Genetic Hearing Loss
Kong, C., Yin, G., Wang, X., & Sun, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400193 · Cited by 12
Tani, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2030-2 · Cited by 12
Liu, J., Hennink, W. E., van Steenbergen, M. J., Zhuo, R., & Jiang, X. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01671e · Cited by 10
Zha, Z., Hu, Y., Mukerabigwi, J. F., Chen, W., Wang, Y., He, C., & Ge, Z. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00672 · Cited by 10
Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus
Cha, S., Lee, S. H., Kang, S. H., Hasan, M. N., Kim, Y. J., Cho, S., & Lee, Y.-K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0129-7 · Cited by 11
Huang, X., Li, Z., Wu, J., Hang, Y., Wang, H., Yuan, L., & Chen, H. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb03045f · Cited by 10
Heldt, C. L. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.06.011 · Cited by 10
Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications
Mills, E. M., Barlow, V. L., Luk, L. Y. P., & Tsai, Y. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09488-2 · Cited by 10
“Although most clinical trials rely on ex vivo gene editing, in which cells are removed from the patient, modified, and then transferred back, in recent years, more trials are being conducted to explore in vivo gene editing in animal models (Naldini 2015).”
BackgroundDiaz‐Dussan, D., Peng, Y., Kumar, P., & Narain, R. (2020) · ACS Macro Letters · doi:10.1021/acsmacrolett.0c00599 · Cited by 10
Hosseinpour, S., Xu, C., & Walsh, L. J. (2021) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.112108 · Cited by 10
A Brief Introduction to Current Cancer Gene Therapy
Kobelt, D., Pahle, J., & Walther, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2441-8_1 · Cited by 13
Kim, T. H., Plona, K. L., & Wynshaw-Boris, A. J. (2016) · Chromosoma · doi:10.1007/s00412-016-0621-6 · Cited by 12
Aronovich, E. L., Hyland, K. A., Hall, B. C., Bell, J. B., Olson, E. R., Urness, M., Hunter, D. W., Ellinwood, N. M., McIvor, R. S., & Hackett, P. B. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.004 · Cited by 14
Genome editing: the breakthrough technology for inherited retinal disease?
Smith, A. J., Carter, S. P., & Kennedy, B. N. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347629 · Cited by 11
Photobiomodulation promotes adenoviral gene transduction in auditory cells
Chang, S., Park, Y., Carpena, N. T., Pham, T., Chung, P., Jung, J. Y., & Lee, M. Y. (2018) · Lasers in Medical Science · doi:10.1007/s10103-018-2605-7 · Cited by 10
Akbulut, H., Cihan, A. Ç., Şahin, G., Tang, Y., & İçlı, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.245 · Cited by 10
“18 The immune system has the potential to eradicate all the tumor cells that have spread throughout the body.”
Tsujimura, M., Kusamori, K., Katsumi, H., Sakane, T., Yamamoto, A., & Nishikawa, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-55269-6 · Cited by 9
Revival of Bioengineered Proteins as Carriers for Nucleic Acids
Scherer, D., Burger, M., & Leroux, J. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00079 · Cited by 10
Engelhard, S., Estruch, M., Qin, S., Engelhard, C. A., Rodríguez-González, F. G., Drilsvik, M., Gonzalez, J. M., Lu, J., Bryder, D., Nerlov, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114475 · Cited by 10
Nuclear‐Targeting Peptides for Cancer Therapy
Yi, X., Hussaın, I., Zhang, P., & Xiao, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400596 · Cited by 10
Polygraph: a software framework for the systematic assessment of synthetic regulatory DNA elements
Lal, A., Gunsalus, L. M., Gupta, A., Biancalani, T., & Eraslan, G. (2025) · Genome biology · doi:10.1186/s13059-025-03584-9 · Cited by 13
Yin, J., Ma, X., Hu, L., & Ye, H. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101425 · Cited by 17
Dharmalingam, P., Balakrishna, M., Voshavar, C., Nadella, R., Rangasami, V. K., Velayudhan, S. R., Abbas, S., Prasad, R. B. N., Kaki, S. S., & Marepally, S. K. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.01.013 · Cited by 10
γ-TRIS: a graph-algorithm for comprehensive identification of vector genomic insertion sites
Calabria, A., Beretta, S., Merelli, I., Spinozzi, G., Brasca, S., Pirola, Y., Benedicenti, F., Tenderini, E., Bonizzoni, P., Milanesi, L., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz747 · Cited by 11
“Results from IS studies allowed to monitor clonal evolution in vivo (Naldini, 2015), including clonal expansions caused by insertional mutagenesis (Afzal et al., 2017; Berry et al., 2017; Sherman et al., 2017; Spinozzi et al., 2017).”
BackgroundCosta, P. F. A., de Abreu, R., Fontana, A. B., Fiedler, H. D., Kirby, A. J., Quina, F. H., Nome, F., & Gerola, A. P. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.12.081 · Cited by 9
Bile Pigment Metabolism and Its Disorders
Roy‐Chowdhury, N., Xia, W., & Roy‐Chowdhury, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00019-7 · Cited by 12
Rapaka, H., Manturthi, S., Arjunan, P., Venkatesan, V., Thangavel, S., Marepally, S. K., & Patri, S. V. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01226 · Cited by 8
Translational Medicine: Towards Gene Therapy of Marfan Syndrome
Kallenbach, K., Remes, A. K., Müller, O. J., Arif, R., Zaradzki, M., & Wagner, A. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11143934 · Cited by 9
“Although adenoviruses proved to have relatively high transduction efficiency in target cells, they are associated with critical safety concerns due to increased inflammation [17,18].”
BackgroundLi, K., Tian, S., Sun, K., Su, Q., Mei, Y., & Niu, W. (2024) · RSC Advances · doi:10.1039/d4ra00352g · Cited by 10
“23 The gene vector is the key for the foreign target gene to enter the host cell, which directly a ff ects the therapeutic e ff ect.”
CRISPR/Cas9, a universal tool for genomic engineering
Smirnov, A. V., Yunusova, A., Lukyanchikova, V., & Баттулин, Н. Р. (2016) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj16.175 · Cited by 15
Safety and Efficacy of Retroviral and Lentiviral Vectors for Gene Therapy
Cesana, D., Volpin, M., Secanechia, Y. N. S., & Montini, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_2 · Cited by 14
In Utero Gene Therapy and Genome Editing
Hartman, H. A., Rossidis, A. C., & Peranteau, W. H. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0117-9 · Cited by 16
A Mixed-Surface Polyamidoamine Dendrimer for In Vitro and In Vivo Delivery of Large Plasmids
Srinageshwar, B., Florendo, M. N., Clark, B., Johnson, K. A., Munro, N., Peruzzaro, S., Antcliff, A., Andrews, M., Figacz, A., Swanson, D. R., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070619 · Cited by 9
Liu, S., Yu, X., Wang, Q., Liu, Z., Xiao, Q., Hou, P., Hu, Y. J., Hou, W., Yang, Z., Guo, D., et al. (2017) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1705.05081 · Cited by 12
Zhang, J.-H., Yang, H., Zhang, J., Liu, Y.-H., He, X., Xiao, Y., & He, X. (2018) · Polymers · doi:10.3390/polym10101080 · Cited by 9
A novel method to purify adenovirus based on increasing salt concentrations in buffer
Ma, J., Su, C., Wang, X., Shu, Y., Hu, S., Zhao, C., Kuang, Y., Chen, Y., Li, Y., Wei, Y., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105090 · Cited by 9
Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune Cells
Fichter, C., Aggarwal, A., Wong, A. K. H., McAllery, S., Mathivanan, V., Hao, B., MacRae, H. H., Churchill, M. J., Gorry, P. R., Roche, M., et al. (2021) · Viruses · doi:10.3390/v13061170 · Cited by 8
“Presently, the gene/cell therapy space is evolving from a niche and exploratory field, into a mature one that promises next-generation personalized healthcare, promising cures or treatments to diseases previously thought to be incurable or untreatable [38,39].”
BackgroundBiomaterials for Targeting Endoplasmic Reticulum in Cancer
Mishra, T., Sengupta, P., & Basu, S. (2024) · Chemistry - An Asian Journal · doi:10.1002/asia.202400250 · Cited by 8
Pinto, M. S.-L., Marti, L., Alarcón, J. F., Sitia, G., Fornaguera, C., Borrós, S., & Guerra‐Rebollo, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113896 · Cited by 8
Pache, M. M., Pangavhane, R. R., Nikam, S. V., Rode, R. B., & Darekar, A. B. (2025) · Research Journal of Science and Technology · doi:10.52711/2231-5713.2025.00045 · Cited by 9
Martins, B., Lopes, C. M., Gomes, A. C., & Lúcio, M. (2025) · Materials Today Nano · doi:10.1016/j.mtnano.2025.100697 · Cited by 12
Radtke, S., Colonna, L., Perez, A. M., Hoffman, M., Kean, L. S., & Kiem, H. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001029 · Cited by 8
Johnson, P. C., Jacobson, C. A., Yi, A., Gaballa, M., Horick, N., Rabideau, D. J., Lindell, K., Depinho, G. D., El-Jawahri, A. R., & Frigault, M. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004567 · Cited by 11
Gene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 14
“Indeed, with a single administration, gene therapy promises to become a potentially lifelong cure, acting at the DNA level, unlike more traditional pharmacological approaches requiring repeated drug administrations and which target downstream components (Naldini, 2015; Dunbar et al., 2018).”
BackgroundNon-viral and viral delivery systems for hemophilia A therapy: recent development and prospects
Zangi, A. R., Amiri, A., Pazooki, P., Soltanmohammadi, F., Hamishehkar, H., & Javadzadeh, Y. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05459-0 · Cited by 8
Exploring Novel Treatment Modalities for Type 1 Diabetes Mellitus: Potential and Prospects
Salama, R. A. A., Patni, M. A., Bahutair, S. N., Wadid, N. A., & Akikwala, M. S. (2024) · Healthcare · doi:10.3390/healthcare12151485 · Cited by 15
“Gene therapy offers a potentially curative approach by correcting genetic defects but faces technical hurdles such as efficient gene delivery and safety concerns [58].”
BackgroundSano, M., Iijima, M., Ohtaka, M., & Nakanishi, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164720 · Cited by 8
CRISPR/Cas9, a universal tool for genomic engineering
Smirnov, A. V., Yunusova, A., Lukyanchikova, V., & Баттулин, Н. Р. (2017) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059717040116 · Cited by 10
“Генная терапия для коррекции заболеваний человека – еще одна область медицины, где применение технологий направленного редактирования генома открывает широ кие перспективы (Cox et al., 2015; Naldini, 2015).”
BackgroundAdvanced Polymers for Nonviral Gene Delivery
Zhou, D., Zeng, M., Gao, Y., Sigen, A., Lyu, J., & Wang, W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00010-1 · Cited by 8
Suñé-Pou, M., Limeres, M. J., Nofrerias, I., Nardi-Ricart, A., Prieto‐Sánchez, S., Yousfi, Y. E., Pérez‐Lozano, P., García‐Montoya, E., Carmona, M. M., Grau, J. R. T., et al. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.04.037 · Cited by 8
Acid‐activated nonviral peptide vector for gene delivery
Ji, K., Xiao, Y., & Zhang, W. (2019) · Journal of Peptide Science · doi:10.1002/psc.3230 · Cited by 8
Chen, S., Guan, L., Zhao, X., Yang, J., Chen, L., Guo, M., Zhao, J., Chen, C., Zhou, Y., Han, Y. H., et al. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200116 · Cited by 8
“…targeting efficacy and safety of optTTF-1 promoter-driven miR-7 expression Many studies have shown that the biological changes of organs or tissues have an important reference value for the wide application of targeted gene therapy (Naldini, 2015; Lux and Scharenberg, 2017; Bucher et al., 2021).”
BackgroundWang, M., He, M., Xu, X., Wu, Z., Tao, J., Yin, F., Luo, K., & Jiang, J. (2023) · Journal of Periodontal Research · doi:10.1111/jre.13133 · Cited by 8
Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia
Hirch, T., Brander, N., Schenk, F., Pollmann, S., Reichenbach, J., Schubert, R., & Modlich, U. (2023) · Scientific Reports · doi:10.1038/s41598-023-46332-4 · Cited by 8
“The stable integration into the genome of HSPC guarantees the lifelong genetic modification of all blood cells 18 .”
Gene Delivery into Cells and Tissues
Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00035-5 · Cited by 10
Mucopolysaccharidosis type III: current clinical trials, challenges and recommendations
Nijmeijer, S. C. M., & Wijburg, F. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1411797 · Cited by 9
Jazbec, K., Jež, M., Smrekar, B., Miceska, S., Rožman, J., Švajger, U., Završnik, J., Malovrh, T., & Rožman, P. J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13024 · Cited by 9
Scarless genome editing: progress towards understanding genotype–phenotype relationships
Elison, G. L., & Açar, M. (2018) · Current Genetics · doi:10.1007/s00294-018-0850-8 · Cited by 9
“Additionally, clinical trials for treatment of genetic disease in adults are already underway (Naldini 2015).”
Production of High-Titer Lentiviral Particles for Stable Genetic Modification of Mammalian Cells
Larcombe, M. R., Manent, J., Chen, J., Mishra, K., Liu, X., & Nefzger, C. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9086-3_4 · Cited by 9
Herrera, L. C., & Shastri, V. P. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.006 · Cited by 8
Bošnjak, M., Kamenšek, U., Serša, G., Stolfa, D., Lavrenčak, J., & Čemažar, M. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9948-z · Cited by 8
“Vol.:(0123456789) (Naldini 2015).”
Hsieh, C.-C., Hsieh, M.-J., Wang, Y.-H., & Liao, Z. (2022) · ACS Omega · doi:10.1021/acsomega.2c03213 · Cited by 8
Meierrieks, F., Rosario, J.-C., Rübeling, L., Asikoglu, H. C., Pflanz, K. B., Pickl, A., Kusch, K., Wolff, M. W., & Graf, B. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465674 · Cited by 7
Zhang, N., Lu, Q., Xu, C., Duan, F., Ma, Y., Zhou, L., Zhang, Y., Ma, Y., Lin, Q., & Lu, K. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123390 · Cited by 7
Lang, W., Liew, S. S., Wang, S., Hong, D., Zhu, L., Du, S., Jiang, L., Yao, S. Q., & Ge, J. (2021) · Chemical Communications · doi:10.1039/d1cc07020g · Cited by 7
Kustova, A. O., Gavrish, M. S., Sergeeva, M. A., Avlasenko, D. A., Kiseleva, A. O., Epifanova, E. A., Babaev, A. A., Mishchenko, T. A., & Vedunova, M. V. (2022) · Brain Sciences · doi:10.3390/brainsci12081039 · Cited by 7
“The use of neurotrophic factors BDNF and GDNF is considered one of the promising therapeutic strategies aimed at increasing the adaptive potential of the CNS for the development of seizure activity.”
BackgroundInfluentialChen, J., Liu, H., Li, C., Chen, X., & Dai, Y. (2023) · Microfluidics and Nanofluidics · doi:10.1007/s10404-023-02701-z · Cited by 7
Ollier, C., Méndez‐Ardoy, A., Ortega‐Caballero, F., Blanco, J. L. J., Bris, N. L., & Tripier, R. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c02854 · Cited by 7
Park, J. S., Hu, J., Chen, L., & Wang, T. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117277 · Cited by 7
Gene therapy: Myth or reality?
Fischer, A. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2016.04.011 · Cited by 11
“Many more projects based on AAV or lentiviral vectors are being tested to treat a variety of inherited disorders affecting brain (mucopolysaccharidosis), muscle (myopathies), or liver (several metabolic diseases) [24].”
Friedmann, T. (2017) · Gene Therapy · doi:10.1038/gt.2017.48 · Cited by 8
Molecular Dynamics Study on Encapsulation of Double Stranded Nucleic Acids into Carbon Nanotubes
Han, Y., & Yang, C. (2018) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.8b05754 · Cited by 7
Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
Schellinger, I. N., Dannert, A., Mattern, K., Raaz, U., & Tsao, P. S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.571076 · Cited by 8
Cortijo-Gutierréz, M., Sánchez-Hernández, S., Tristán‐Manzano, M., Maldonado‐Pérez, N., López-Onieva, L., Real, P. J., Herrera, C., Marchal, J. A., Martín, F., & Benabdellah, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081217 · Cited by 8
“Up to now, the most commonly used viral vectors in most clinical trials have been adenoviruses (AdVs), γ-retroviral vectors (RVs), adeno-associated vectors (AAVs), and lentiviral vectors (LVs) [1,7], with the latter presenting several attractive features, especially for applications where transgene integration is requ…”
BackgroundMethodWatanabe, Y., Nihonyanagi, H., Numano, R., Shibata, T., Takashima, K., & Kurita, H. (2022) · Sensors · doi:10.3390/s22072494 · Cited by 8
Construction of Degradable and Amphiphilic Triblock Polymer Carriers for Effective Delivery of siRNA
Yan, Y., Zhu, F., Su, H., Liu, X., Ren, Q., Huang, F., Ye, W., Zhao, M., Zhao, Y., Zhao, J., et al. (2022) · Macromolecular Bioscience · doi:10.1002/mabi.202200232 · Cited by 7
Kuroda, M., Saitō, Y., Aso, M., & Yokote, K. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00786 · Cited by 7
Kim, M. G., Jo, S. D., Jeong, J. H., & Kim, S. H. (2018) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2018.04.005 · Cited by 7
Reifarth, M., Schubert, U. S., & Hoeppener, S. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700254 · Cited by 9
Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013
Suzuki, Y., Togano, T., Ohto, H., & Kume, H. (2018) · Medical Mycology Journal · doi:10.3314/mmj.18-00003 · Cited by 10
Tissue-Specific Delivery of Oligonucleotides
Xia, X., Pollock, N., Zhou, J., & Rossi, J. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9670-4_2 · Cited by 8
Bioengineering strategies for gene delivery
Shams, S., & Silva, E. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816221-7.00004-5 · Cited by 10
Peptide modified polycations with pH triggered lytic activity for efficient gene delivery
Chen, X., Xu, K. L., Yu, J. X., Zhao, X., Zhang, Q., Zhang, Y., & Cheng, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01231a · Cited by 7
The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics
Xiao, F., Liu, J., Zheng, Y., Quan, Z., Sun, W., Fan, Y., Luo, C., Li, H., & Wu, X. (2020) · Journal of Biomaterials Applications · doi:10.1177/0885328220975249 · Cited by 7
“Besides, gene fragments are not stable in the blood, and complex cellular and tissue barriers must be overcomed to deliver new genetic information into the target cell to drive proficient expression of a therapeutic molecule.(21) There are two kinds of gene delivery vectors: viral and no-viral vectors.”
BackgroundSynthetic Delivery Systems for DNA, siRNA, and mRNA Based on Pyridinium Amphiphiles
Ilies, M. A., Satyal, U., & Sharma, V. D. (2017) · ACS symposium series · doi:10.1021/bk-2017-1271.ch001 · Cited by 8
Molecular barcoding of viral vectors enables mapping and optimization of mRNAtrans-splicing
Davidsson, M., Díaz-Fernández, P., Torroba, M., Schwich, O. D., Aldrin-Kirk, P., Quintino, L., Heuer, A., Wang, G., Lundberg, C., & Björklund, T. (2018) · RNA · doi:10.1261/rna.063925.117 · Cited by 7
“By delivering DNA/RNA via viral vectors it is possible to repair or disrupt disease causing genes and also to introduce novel genes (Puttaraju et al. 1999; Mansfield et al. 2000; Jinek et al. 2012; Naldini 2015).”
BackgroundZhou, A., Zhang, Y., Chen, W., Ren, J., & Ning, X. (2026) · ACS Nano · doi:10.1021/acsnano.5c21849 · Cited by 7
PHP.B/eB Vectors Bring New Successes to Gene Therapy for Brain Diseases
Reynaud-Dulaurier, R., & Decressac, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.582979 · Cited by 7
“…using viral vectors showed outstanding preclinical and clinical benefits for inherited pediatric diseases, in particular those for which non-cell autonomous mechanisms such as cross-correction is effective (i.e., X-linked adrenoleukodystrophy or Batten’s disease) (Naldini, 2015; Aubourg, 2016).”
BackgroundTreatment Considerations to Overcome the Barriers Associated with Skin Cancer Targeting
Kumari, P., Alam, A., Dhoundiyal, S., Kaur, A., & Yadav, S. (2023) · Current Cancer Therapy Reviews · doi:10.2174/0115733947253349231027043858 · Cited by 9
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.